Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy... Show more
The 50-day moving average for DGNOF moved above the 200-day moving average on October 07, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Momentum Indicator moved above the 0 level on September 25, 2025. You may want to consider a long position or call options on DGNOF as a result. In of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for DGNOF just turned positive on September 30, 2025. Looking at past instances where DGNOF's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .
DGNOF moved above its 50-day moving average on September 26, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DGNOF advanced for three days, in of 87 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 80 cases where DGNOF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for DGNOF moved out of overbought territory on October 17, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 52 cases where DGNOF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DGNOF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
DGNOF broke above its upper Bollinger Band on October 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DGNOF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DGNOF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (108.696) is normal, around the industry mean (21.732). P/E Ratio (0.000) is within average values for comparable stocks, (83.279). DGNOF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.618). DGNOF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (384.615) is also within normal values, averaging (70.594).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Industry ServicestotheHealthIndustry
A.I.dvisor tells us that DGNOF and KNAMF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DGNOF and KNAMF's prices will move in lockstep.
Ticker / NAME | Correlation To DGNOF | 1D Price Change % | ||
---|---|---|---|---|
DGNOF | 100% | -5.34% | ||
KNAMF - DGNOF | 27% Poorly correlated | N/A | ||
NEXOY - DGNOF | 23% Poorly correlated | -1.36% | ||
NEXOF - DGNOF | 20% Poorly correlated | N/A | ||
EBYH - DGNOF | 10% Poorly correlated | N/A | ||
LFMD - DGNOF | 6% Poorly correlated | -5.44% | ||
More |
Ticker / NAME | Correlation To DGNOF | 1D Price Change % |
---|---|---|
DGNOF | 100% | -5.34% |
Health Services category (427 stocks) | 9% Poorly correlated | -1.10% |
Services to the Health Industry category (93 stocks) | 9% Poorly correlated | -2.28% |